Development of vorinostat: Current applications and future perspectives for cancer therapy

Cancer Letters

Volumn 280, Issue 2, 2009, Pages 201-210

  Richon, Victoria M ^a   Garcia Vargas, Jose ^a   Hardwick, James S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Epigenetics; HDAC; Histone deacetylase; SAHA; Suberoylanilide hydroxamic acid; Vorinostat

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BICALUTAMIDE; BORTEZOMIB; CISPLATIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DNA METHYLTRANSFERASE INHIBITOR; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; GEMCITABINE; IMATINIB; IRINOTECAN; PERIFOSINE; PROTEASOME INHIBITOR; RETINOIC ACID; SORAFENIB; TAMOXIFEN; TANESPIMYCIN; TEMOZOLOMIDE; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VORINOSTAT; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIZATION; SHORT SURVEY; SOLID TUMOR;

ANIMALIA;

EID: 67349095775     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.01.002     Document Type: Review

References (129)

1. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
2. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002) 415-428
3. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1 (2001) 194-202
4. Timmermann S., Lehrmann H., Polesskaya A., and Harel-Bellan A. Histone acetylation and disease. Cell. Mol. Life Sci. 58 (2001) 728-736
5. Wang C., Fu M., Mani S., Wadler S., Senderowicz A.M., and Pestell R.G. Histone acetylation and the cell-cycle in cancer. Front. Biosci. 6 (2001) 610-629
6. Lin R.J., Nagy L., Inoue S., Shao W., Miller Jr. W.H., and Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391 (1998) 811-814
7. McKenna N.J., Lanz R.B., and O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20 (1999) 321-344
8. Dhordain P., Albagli O., Lin R.J., Ansieau S., Quief S., Leutz A., Kerckaert J.P., Evans R.M., and Leprince D. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc. Natl. Acad. Sci. USA 94 (1997) 10762-10767
9. Gregoretti I.V., Lee Y.M., and Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338 (2004) 17-31
10. Lehrmann H., Pritchard L.L., and Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. 86 (2002) 41-65
11. Marks P.A., and Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25 (2007) 84-90
12. Yang X.J., and Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell. Biol. 9 (2008) 206-218
13. Frye R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273 (2000) 793-798
14. Yamamoto H., Schoonjans K., and Auwerx J. Sirtuin functions in health and disease. Mol. Endocrinol. 21 (2007) 1745-1755
15. Boyault C., Zhang Y., Fritah S., Caron C., Gilquin B., Kwon S.H., Garrido C., Yao T.P., Vourc'h C., Matthias P., and Khochbin S. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev. 21 (2007) 2172-2181
16. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., and Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115 (2003) 727-738
17. Valenzuela-Fernandez A., Cabrero J.R., Serrador J.M., and Sanchez-Madrid F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 18 (2008) 291-297
18. Gao Y.S., Hubbert C.C., Lu J., Lee Y.S., Lee J.Y., and Yao T.P. Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol. Cell. Biol. 27 (2007) 8637-8647
19. Zhang X., Yuan Z., Zhang Y., Yong S., Salas-Burgos A., Koomen J., Olashaw N., Parsons J.T., Yang X.J., Dent S.R., Yao T.P., Lane W.S., and Seto E. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol. Cell 27 (2007) 197-213
20. Boyault C., Sadoul K., Pabion M., and Khochbin S. HDAC6 at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 26 (2007) 5468-5476
21. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., Yoshida M., Toft D.O., Pratt W.B., and Yao T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18 (2005) 601-607
22. Moradei O., Maroun C.R., Paquin I., and Vaisburg A. Histone deacetylase inhibitors: latest developments, trends and prospects. Curr. Med. Chem. Anticancer Agents 5 (2005) 529-560
23. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., and Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 95 (1998) 3003-3007
24. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs III W.H., Edeen P.T., Floyd M., Ford J.M., Grotzfeld R.M., Herrgard S., Insko D.E., Mehta S.A., Patel H.K., Pao W., Sawyers C.L., Varmus H., Zarrinkar P.P., and Lockhart D.J. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 102 (2005) 11011-11016
25. Tanaka M., Levy J., Terada M., Breslow R., Rifkind R.A., and Marks P.A. Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds. Proc. Natl. Acad. Sci. USA 72 (1975) 1003-1006
26. Reuben R.C., Wife R.L., Breslow R., Rifkind R.A., and Marks P.A. A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc. Natl. Acad. Sci. USA 73 (1976) 862-866
27. Breslow R., Jursic B., Yan Z.F., Friedman E., Leng L., Ngo L., Rifkind R.A., and Marks P.A. Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc. Natl. Acad. Sci. USA 88 (1991) 5542-5546
28. Richon V.M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., Civoli F., Breslow R., Rifkind R.A., and Marks P.A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA 93 (1996) 5705-5708
29. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., and Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60 (2000) 5165-5170
30. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., and Richon V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23 (2005) 3923-3931
31. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., Chiao J.H., Reilly J.F., Ricker J.L., Richon V.M., and Frankel S.R. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 (2007) 31-39
32. Olsen E.A., Kim Y.H., Kuzel T.M., Pacheco T.R., Foss F.M., Parker S., Frankel S.R., Chen C., Ricker J.L., Arduino J.M., and Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25 (2007) 3109-3115
33. E. Galanis, K.A. Jaeckle, M.J. Maurer, J.A. Reid, M. Ames, J.S. Hardwick, J.F. Reilly, A. Loboda, M. Nebozhyn, V.R. Fantin, V.M. Richon, B. Scheithauer, C. Giannini, J. Zweibel, J.C. Buckner, Phase II trial of vorinostat (SAHA) in recurrent glioblastoma multiforme: a north central cancer treatment group study, J. Clin. Oncol., in press.
34. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., Faderl S., Koller C., Morris G., Rosner G., Loboda A., Fantin V.R., Randolph S.S., Hardwick J.S., Reilly J.F., Chen C., Ricker J.L., Secrist J.P., Richon V.M., Frankel S.R., and Kantarjian H.M. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111 (2008) 1060-1066
35. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97 (2000) 10014-10019
36. Vrana J.A., Decker R.H., Johnson C.R., Wang Z., Jarvis W.D., Richon V.M., Ehinger M., Fisher P.B., and Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18 (1999) 7016-7025
37. Zhang C., Richon V., Ni X., Talpur R., and Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J. Invest. Dermatol. 125 (2005) 1045-1052
38. Rascle A., Johnston J.A., and Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol. Cell. Biol. 23 (2003) 4162-4173
39. Xu M., Nie L., Kim S.H., and Sun X.H. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta. EMBO J. 22 (2003) 893-904
40. Fantin V.R., Loboda A., Paweletz C.P., Hendrickson R.C., Pierce J.W., Roth J.A., Li L., Gooden F., Korenchuk S., Hou X.S., Harrington E.A., Randolph S., Reilly J.F., Ware C.M., Kadin M.E., Frankel S.R., and Richon V.M. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 68 (2008) 3785-3794
41. Gu W., and Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90 (1997) 595-606
42. Qian D.Z., Kachhap S.K., Collis S.J., Verheul H.M., Carducci M.A., Atadja P., and Pili R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 66 (2006) 8814-8821
43. Williams R.J. Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin. Invest. Drugs 10 (2001) 1571-1573
44. Ferreira R., Magnaghi-Jaulin L., Robin P., Harel-Bellan A., and Trouche D. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc. Natl. Acad. Sci. USA 95 (1998) 10493-10498
45. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X.F., and Yao T.P. HDAC6 is a microtubule-associated deacetylase. Nature 417 (2002) 455-458
46. Rao R., Fiskus W., Yang Y., Lee P., Joshi R., Fernandez P., Mandawat A., Atadja P., Bradner J.E., and Bhalla K. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 112 (2008) 1886-1893
47. Secrist J.P., Zhou X., and Richon V.M. HDAC inhibitors for the treatment of cancer. Curr. Opin. Invest. Drugs 4 (2003) 1422-1427
48. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 (2007) 5541-5552
49. Munster P.N., Troso-Sandoval T., Rosen N., Rifkind R., Marks P.A., and Richon V.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61 (2001) 8492-8497
50. He L.Z., Tolentino T., Grayson P., Zhong S., Warrell Jr. R.P., Rifkind R.A., Marks P.A., Richon V.M., and Pandolfi P.P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108 (2001) 1321-1330
51. Eyupoglu I.Y., Hahnen E., Buslei R., Siebzehnrubl F.A., Savaskan N.E., Luders M., Trankle C., Wick W., Weller M., Fahlbusch R., and Blumcke I. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J. Neurochem. 93 (2005) 992-999
52. Huang L., and Pardee A.B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. 6 (2000) 849-866
53. Kumagai T., Wakimoto N., Yin D., Gery S., Kawamata N., Takai N., Komatsu N., Chumakov A., Imai Y., and Koeffler H.P. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int. J. Cancer 121 (2007) 656-665
54. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13 (2001) 477-483
55. Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., Schlossman R., Chauhan D., Munshi N.C., Hideshima T., Richon V.M., Marks P.A., and Anderson K.C. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101 (2003) 4055-4062
56. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., and Johnstone R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 98 (2001) 10833-10838
57. Sakajiri S., Kumagai T., Kawamata N., Saitoh T., Said J.W., and Koeffler H.P. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp. Hematol. 33 (2005) 53-61
58. Deroanne C.F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., Blacher S., Verdin E., Foidart J.M., Nusgens B.V., and Castronovo V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21 (2002) 427-436
59. Ruefli A.A., Bernhard D., Tainton K.M., Kofler R., Smyth M.J., and Johnstone R.W. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int. J. Cancer 99 (2002) 292-298
60. Cohen L.A., Marks P.A., Rifkind R.A., Amin S., Desai D., Pittman B., and Richon V.M. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res. 22 (2002) 1497-1504
61. Cohen L.A., Amin S., Marks P.A., Rifkind R.A., Desai D., and Richon V.M. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res. 19 (1999) 4999-5005
62. Desai D., Das A., Cohen L., el-Bayoumy K., and Amin S. Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res. 23 (2003) 499-503
63. Camphausen K., and Tofilon P.J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol. 25 (2007) 4051-4056
64. Karagiannis T.C., and El Osta A. Chromatin modifications and DNA double-strand breaks: the current state of play. Leukemia 21 (2007) 195-200
65. Kumar K.S., Sonnemann J., Hong l.T., Buurman C., Adler F., Maass M., Volker U., and Beck J.F. Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma. Anticancer Res. 27 (2007) 465-470
66. Karagiannis T.C., and El Osta A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25 (2006) 3885-3893
67. Zhang Y., Adachi M., Zou H., Hareyama M., Imai K., and Shinomura Y. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 65 (2006) 859-866
68. Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S.M., and Harari P.M. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 223-229
69. Jung M., Kozikowski A., and Dritschilo A. Rational design and development of radiation-sensitizing histone deacetylase inhibitors. Chem. Biodivers. 2 (2005) 1452-1461
70. Munshi A., Tanaka T., Hobbs M.L., Tucker S.L., Richon V.M., and Meyn R.E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer Ther. 5 (2006) 1967-1974
71. Sonnemann J., Kumar K.S., Heesch S., Muller C., Hartwig C., Maass M., Bader P., and Beck J.F. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int. J. Oncol. 28 (2006) 755-766
72. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., and Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12 (1998) 2831-2841
73. Kim G.D., Choi Y.H., Dimtchev A., Jeong S.J., Dritschilo A., and Jung M. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J. Biol. Chem. 274 (1999) 31127-31130
74. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 389 (1997) 349-352
75. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12 (1998) 599-606
76. Kim M.S., Blake M., Baek J.H., Kohlhagen G., Pommier Y., and Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 63 (2003) 7291-7300
77. Rikiishi H., Shinohara F., Sato T., Sato Y., Suzuki M., and Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int. J. Oncol. 30 (2007) 1181-1188
78. Marchion D.C., Bicaku E., Daud A.I., Richon V., Sullivan D.M., and Munster P.N. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J. Cell. Biochem. 92 (2004) 223-237
79. Ocker M., Alajati A., Ganslmayer M., Zopf S., Luders M., Neureiter D., Hahn E.G., Schuppan D., and Herold C. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J. Cancer Res. Clin. Oncol. 131 (2005) 385-394
80. Marchion D.C., Bicaku E., Turner J.G., Daud A.I., Sullivan D.M., and Munster P.N. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin. Cancer Res. 11 (2005) 8467-8475
81. Ramalingam S.S., Parise R.A., Ramanathan R.K., Lagattuta T.F., Musguire L.A., Stoller R.G., Potter D.M., Argiris A.E., Zwiebel J.A., Egorin M.J., and Belani C.P. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin. Cancer Res. 13 (2007) 3605-3610
82. Gore S.D. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat. Clin. Pract. Oncol. 2 (2005) S30-S35
83. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21 (2002) 5427-5440
84. Santini V., Kantarjian H.M., and Issa J.P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann. Intern. Med. 134 (2001) 573-586
85. Lemaire M., Momparler L.F., Farinha N.J., Bernstein M., and Momparler R.L. Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by phenylbutyrate on L1210 leukemic cells. Leuk. Lymphoma 45 (2004) 147-154
86. Shaker S., Bernstein M., Momparler L.F., and Momparler R.L. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk. Res. 27 (2003) 437-444
87. Shaker S., Bernstein M., and Momparler R.L. Antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells. Oncol. Rep. 11 (2004) 1253-1256
88. Yang H., Hoshino K., Sanchez-Gonzalez B., Kantarjian H., and Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk. Res. 29 (2005) 739-748
89. Silverman L.R., Verma A., Odchimar-Reissig R., Cozza A., Najfeld V., Licht J.D., and Zwiebel J.A. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York cancer consortium study. J. Clin. Oncol. 26 (2008) 7000 (ASCO Meeting Abstracts)
90. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Andtbacka R.H., Dunner Jr. K., Pal A., Bornmann W.G., Chiao P.J., Huang P., Xiong H., Abbruzzese J.L., and McConkey D.J. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 66 (2006) 3773-3781
91. Nawrocki S.T., Carew J.S., Maclean K.H., Courage J.F., Huang P., Houghton J.A., Cleveland J.L., Giles F.J., and McConkey D.J. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 112 (2008) 2917-2926
92. Heider U., von Metzler I., Kaiser M., Rosche M., Sterz J., Rotzer S., Rademacher J., Jakob C., Fleissner C., Kuckelkorn U., Kloetzel P.M., and Sezer O. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur. J. Haematol. 80 (2008) 133-142
93. Emanuele S., Lauricella M., Carlisi D., Vassallo B., D'Anneo A., Di Fazio P., Vento R., and Tesoriere G. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor bortezomib. Apoptosis 12 (2007) 1327-1338
94. Pei X.Y., Dai Y., and Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 10 (2004) 3839-3852
95. Yu C., Rahmani M., Conrad D., Subler M., Dent P., and Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102 (2003) 3765-3774
96. Kyle R.A., and Rajkumar S.V. Multiple myeloma. Blood 111 (2008) 2962-2972
97. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Rocha K., Kumaraswamy S., Boyapalle S., Atadja P., Seto E., and Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280 (2005) 26729-26734
98. Rahmani M., Yu C., Dai Y., Reese E., Ahmed W., Dent P., and Grant S. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res. 63 (2003) 8420-8427
99. Rahmani M., Reese E., Dai Y., Bauer C., Kramer L.B., Huang M., Jove R., Dent P., and Grant S. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol. Pharmacol. 67 (2005) 1166-1176
100. Marrocco D.L., Tilley W.D., Bianco-Miotto T., Evdokiou A., Scher H.I., Rifkind R.A., Marks P.A., Richon V.M., and Butler L.M. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol. Cancer Ther. 6 (2007) 51-60
101. Hodges-Gallagher L., Valentine C.D., Bader S.E., and Kushner P.J. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res. Treat. 105 (2007) 297-309
102. Zhang C., Ni X., Talpur R., Richon V., and Duvic M. SAHA, a deacetylase inhibitor, induces apoptosis in cutaneous T-cell lymphoma cells and is synergistic with 5-Aza-2 deoxycytidine. Blood 102 (2003) (American Society of Hematology Annual Meeting Abstract)
103. Denlinger C.E., Rundall B.K., and Jones D.R. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J. Thorac. Cardiovasc. Surg. 128 (2004) 740-748
104. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., Akiyama M., Chauhan D., Munshi N., Gu X., Bailey C., Joseph M., Libermann T.A., Richon V.M., Marks P.A., and Anderson K.C. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA 101 (2004) 540-545
105. Bali P., Pranpat M., Swaby R., Fiskus W., Yamaguchi H., Balasis M., Rocha K., Wang H.G., Richon V., and Bhalla K. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin. Cancer Res. 11 (2005) 6382-6389
106. Almenara J., Rosato R., and Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16 (2002) 1331-1343
107. Gao N., Dai Y., Rahmani M., Dent P., and Grant S. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol. Pharmacol. 66 (2004) 956-963
108. Mitchell C., Park M.A., Zhang G., Yacoub A., Curiel D.T., Fisher P.B., Roberts J.D., Grant S., and Dent P. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol. Cancer Ther. 6 (2007) 3101-3112
109. Lillehammer T., Engesaeter B.O., Prasmickaite L., Maelandsmo G.M., Fodstad O., and Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J. Gene Med. 9 (2007) 440-451
110. Nakata S., Yoshida T., Horinaka M., Shiraishi T., Wakada M., and Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23 (2004) 6261-6271
111. Rahmani M., Yu C., Reese E., Ahmed W., Hirsch K., Dent P., and Grant S. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene 22 (2003) 6231-6242
112. Rosato R.R., Almenara J.A., Dai Y., and Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2 (2003) 1273-1284
113. Singh T.R., Shankar S., and Srivastava R.K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24 (2005) 4609-4623
114. Sonnemann J., Gange J., Kumar K.S., Muller C., Bader P., and Beck J.F. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest. New Drugs 23 (2005) 99-109
115. Yu C., Dasmahapatra G., Dent P., and Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia 19 (2005) 1579-1589
116. Rahmani M., Reese E., Dai Y., Bauer C., Payne S.G., Dent P., Spiegel S., and Grant S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res. 65 (2005) 2422-2432
117. Dai Y., Rahmani M., Dent P., and Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol. Cell. Biol. 25 (2005) 5429-5444
118. Arnold N.B., Arkus N., Gunn J., and Korc M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin. Cancer Res. 13 (2007) 18-26
119. Rundall B.K., Denlinger C.E., and Jones D.R. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 138 (2005) 360-367
120. Sonnemann J., Bumbul B., and Beck J.F. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol. Cancer Ther. 6 (2007) 2976-2984
121. Spiller S.E., Ditzler S.H., Pullar B.J., and Olson J.M. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J. Neurooncol. 87 (2008) 133-141
122. Fiskus W., Wang Y., Joshi R., Rao R., Yang Y., Chen J., Kolhe R., Balusu R., Eaton K., Lee P., Ustun C., Jillella A., Buser C.A., Peiper S., and Bhalla K. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin. Cancer Res. 14 (2008) 6106-6115
123. Nimmanapalli R., Fuino L., Stobaugh C., Richon V., and Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101 (2003) 3236-3239
124. Yu C., Rahmani M., Almenara J., Subler M., Krystal G., Conrad D., Varticovski L., Dent P., and Grant S. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res. 63 (2003) 2118-2126
125. Fiskus W., Pranpat M., Balasis M., Bali P., Estrella V., Kumaraswamy S., Rao R., Rocha K., Herger B., Lee F., Richon V., and Bhalla K. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin. Cancer Res. 12 (2006) 5869-5878
126. Dasmahapatra G., Yerram N., Dai Y., Dent P., and Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin. Cancer Res. 13 (2007) 4280-4290
127. Park M.A., Zhang G., Martin A.P., Hamed H., Mitchell C., Hylemon P.B., Graf M., Rahmani M., Ryan K., Liu X., Spiegel S., Norris J., Fisher P.B., Grant S., and Dent P. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol. Ther. 7 (2008) 1648-1662
128. Zhang G., Park M.A., Mitchell C., Hamed H., Rahmani M., Martin A.P., Curiel D.T., Yacoub A., Graf M., Lee R., Roberts J.D., Fisher P.B., Grant S., and Dent P. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin. Cancer Res. 14 (2008) 5385-5399
129. Seo S.K., Jin H.O., Lee H.C., Woo S.H., Kim E.S., Yoo D.H., Lee S.J., An S., Rhee C.H., Hong S.I., Choe T.B., and Park I.C. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol. Pharmacol. 73 (2008) 1005-1012